AI-Assisted Drug Discovery: Why Governed Data Is the Rate Limiter, Not Model Capability
The pharmaceutical industry has invested heavily in artificial intelligence over the past decade. The results have been uneven — not because the models are inadequate, but because the data feeding those models is. In project after project, the root cause of AI failure in drug discovery is not model architecture. It is the quality, consistency, […]
